Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a study to obtain clinical experience of 323U66 SR for elderly patients with depression in repeat-dose of 323U66 SR up to 300mg/day, and to conduct exploratory investigation on safety, efficacy and pharmacokinetics profile in elderly patients with depression.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 323U66 SR | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) Total Score at Week 8 | The Hamilton Rating Scale for Depression (HAM D) contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). | Baseline and Week 8 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) Total Score at Week 4 | The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). | Baseline and Week 4 |
Not provided
Inclusion criteria:
Target disease: Patients diagnosed as having the following primary disease and current major depressive episode for at least 8 weeks on the basis of DSM-IV-TR criteria.
HAM-D (17 items) total score >/=18.
Age: >/=65 years old (at the time of informed consent)
Gender: Male or female.
Inpatient or outpatient status: Either
Informed consent: The subject himself/herself must give written informed consent.
Exclusion criteria:
Patients with predisposition to seizure (who currently have or have a past history of seizure, febrile convulsive seizure in infancy, cerebral tumour, cerebrovascular disorder or head injury, who have a family history of idiopathic seizure, patients with diabetes who have been treated with oral hypoglycaemics or insulin, or who use drugs lowering the threshold of seizure)
Patients who currently have or have a past history of the following disorders:
Patients with a history of manic episode
Patients with a past or current DSM- IV-TR diagnosis of schizophrenia or other psychotic disorder
Patients with a current DSM-IV-TR Axis II diagnosis (e.g., antisocial or borderline personality disorder)
Patients starting psychotherapy (except for supportive psychotherapy not aimed at therapeutic efficacy and unlikely to affect efficacy evaluation) and standardized cognitive behaviour therapy within 12 weeks prior to the start of the treatment phase
Patients with a diagnosis of substance abuse (alcohol or drug) by the DSM-IV-TR criteria or with a diagnosis of substance dependence within 1 year prior to the start of the treatment phase
Patients who have received electroconvulsive therapy within 24 weeks prior to the start of the treatment phase
Patients who have taken MAO inhibitors (selegiline hydrochloride) within 2 weeks prior to the start of the treatment phase
Patients who have taken another investigational drug within 12 weeks prior to the start of the pre-treatment phase
Patients who have attempted suicide within 24 weeks prior to the start of the treatment phase, or patients for whom the score of the suicide-related item of HAM-D is >/=3, or patients in whom the risk of suicide is judged to be high by the investigator (sub-investigator).
Patients in whom the risk of homicide is judged to be high by the investigator (sub-investigator).
Patients with a history of hypersensitivity to 323U66
Patients with serious cerebral disease
Patients who have ECG or clinical evidence of any cardiac condition that the investigator (sub-investigator) assesses the subject is predisposed to ischemia or arrhythmia
Patients with serious physical symptoms (i.e. cardiac/hepatic/renal disorder, hematopoietic disorder).
The index of seriousness is Grade 3 of "Criteria for classification of seriousness of adverse drug reactions to pharmaceutical products, etc." (PAB/PSD No.80 in 1992).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials, MD | GlaxoSmithKline | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GSK Investigational Site | Fukuoka | 815-0041 | Japan | |||
| GSK Investigational Site |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Bupropion SR | Dose level 1 = 100mg tablet of Bupropion SR morning, after one week dose 1, increased to Dose 2 twice daily 100mg of Bupropion SR morning and evening, after one week at dose 2 could increase to Dose 3 150mg Bupropion twice daily morning and evening. Subjects stayed at dose level 3 for 6 weeks if tolerated. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Bupropion SR |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) Total Score at Week 8 | The Hamilton Rating Scale for Depression (HAM D) contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). | Full Analysis Set consisted of all subjects in the safety population who had baseline and at least on post-baseline efficacy data and met the objectively-measured major eligibility criteria. Last observation carried forward method for missing data. | Posted | Mean | Standard Deviation | Scores on a scale | Baseline and Week 8 |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Bupropion SR | Dose level 1 = 100mg tablet of Bupropion SR morning, after one week dose 1, increased to Dose 2 twice daily 100mg of Bupropion SR morning and evening, after one week at dose 2 could increase to Dose 3 150mg Bupropion twice daily morning and evening. Subjects stayed at dose level 3 for 6 weeks if tolerated. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Suicide attempt | Psychiatric disorders | MedDRA | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | MedDRA | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| GSK Response Center | GlaxoSmithKline | 866-435-7343 |
Not provided
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| D003863 | Depression |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
| D001526 | Behavioral Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Percentage Change From Baseline in Hamilton Rating Scale for Depression (HAM-D)Total Score at Week 8 | The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). | Baseline and Week 8 |
| Percentage of Responders Based on the Hamilton Rating Scale for Depression (HAM-D) at Week 4 | The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). Responders are defined as subjects that had a decrease of >/= 50% total score on the HAM D. | Week 4 |
| Percentage of Responders Based on the Hamilton Rating Scale for Depression (HAM-D) at Week 8 | The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). Responders are defined as subjects that had a decrease of >/= 50% total score on the HAM D. | Week 8 |
| Percentage of Remitters Based on the Hamilton Rating Scale for Depression (HAM-D) at Week 4 | The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). Remitters are defined as subjects with a HAM D total score of \ | Week 4 |
| Percentage of Remitters Based on the Hamilton Rating Scale for Depression (HAM-D) at Week 8 | The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). Remitters are defined as subjects with a HAM D total score of \ | Week 8 |
| Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) of Each Question's Score at Week 4 | The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). | Baseline and Week 4 |
| Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) for Each Question's Score at Week 8 | The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). | Baseline and Week 8 |
| Percentage of Change From Baseline in Hamilton Rating Scale for Depression (HAM-D)for Each Question's Score at Week 4 | The Hamilton Rating Scale for Depression (HAM-D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM-D score range from 0 (not ill) to 53 (severely ill). | Baseline and Week 4 |
| Percentage of Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) for Each Question's Score at Week 8 | The Hamilton Rating Scale for Depression (HAM-D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). | Baseline and Week 8 |
| Hamilton Rating Scale for Depression (HAM-D) Total Score at Week 4 and Week 8 | The Hamilton Rating Scale for Depression (HAM-D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). | Week 4 and Week 8 |
| Percentage of Responders Based on the Clinical Global Impression - Global Improvement Score (CGI-I)at Week 4 and Week 8 | The CGI-I assesses the investigator's impression of the patient's current illness. The time span is the week before the rating and the score ranges from 1 (very much improved) to 7 (very much worse). Responders are subjects that have a score of 1 (very much improved) or 2 (much improved) on the CGI-I. | Week 4 and Week 8 |
| Change From Baseline in Clinical Global Impression (CGI) Severity of Illness Score at Weeks 1, 2, 3, 4, 8 | The CGI-S assesses the investigator's impression of the severity of the patient's current illness. The time span is the week before the rating and the score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). | Baseline, Weeks 1, 2, 3, 4, 8 |
| Adverse Events (>=5% Incidence) | Baseline through Week 8 |
| Serious Adverse Events | Baseline through Week 8 |
| Fukushima |
| 961-0021 |
| Japan |
| GSK Investigational Site | Kumamoto | 861-8002 | Japan |
| GSK Investigational Site | Nagano | 395-0056 | Japan |
| GSK Investigational Site | Nagano | 399-8695 | Japan |
| GSK Investigational Site | Saitama | 332-0012 | Japan |
| GSK Investigational Site | Tokyo | 164-0012 | Japan |
| GSK Investigational Site | Tokyo | 170-0002 | Japan |
| GSK Investigational Site | Tokyo | 189-0012 | Japan |
| Withdrawal by Subject |
|
| Other |
|
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Number | Participants |
|
| Counts |
|---|
| Participants |
|
|
| Secondary | Percentage Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) Total Score at Week 4 | The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). | Full Analysis Set consisted of all subjects in the safety population who had baseline and at least on post-baseline efficacy data and met the objectively-measured major eligibility criteria. Last observation carried forward method for missing data. | Posted | Mean | Standard Deviation | Percentage of Change | Baseline and Week 4 |
|
|
|
| Secondary | Percentage Change From Baseline in Hamilton Rating Scale for Depression (HAM-D)Total Score at Week 8 | The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). | Full Analysis Set consisted of all subjects in the safety population who had baseline and at least on post-baseline efficacy data and met the objectively-measured major eligibility criteria. Last observation carried forward method for missing data. | Posted | Mean | Standard Deviation | Percentage of Change | Baseline and Week 8 |
|
|
|
| Secondary | Percentage of Responders Based on the Hamilton Rating Scale for Depression (HAM-D) at Week 4 | The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). Responders are defined as subjects that had a decrease of >/= 50% total score on the HAM D. | Full Analysis Set consisted of all subjects in the safety population who had baseline and at least on post-baseline efficacy data and met the objectively-measured major eligibility criteria. Last observation carried forward method for missing data. | Posted | Number | Percentage of Responders | Week 4 |
|
|
|
| Secondary | Percentage of Responders Based on the Hamilton Rating Scale for Depression (HAM-D) at Week 8 | The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). Responders are defined as subjects that had a decrease of >/= 50% total score on the HAM D. | Full Analysis Set consisted of all subjects in the safety population who had baseline and at least on post-baseline efficacy data and met the objectively-measured major eligibility criteria. Last observation carried forward method for missing data. | Posted | Number | Percentage of Responders | Week 8 |
|
|
|
| Secondary | Percentage of Remitters Based on the Hamilton Rating Scale for Depression (HAM-D) at Week 4 | The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). Remitters are defined as subjects with a HAM D total score of \ | Full Analysis Set consisted of all subjects in the safety population who had baseline and at least on post-baseline efficacy data and met the objectively-measured major eligibility criteria. Last observation carried forward method for missing data. | Posted | Number | Percentage of Remitters | Week 4 |
|
|
|
| Secondary | Percentage of Remitters Based on the Hamilton Rating Scale for Depression (HAM-D) at Week 8 | The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). Remitters are defined as subjects with a HAM D total score of \ | Full Analysis Set consisted of all subjects in the safety population who had baseline and at least on post-baseline efficacy data and met the objectively-measured major eligibility criteria. Last observation carried forward method for missing data. | Posted | Number | Percentage of Remitters | Week 8 |
|
|
|
| Secondary | Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) of Each Question's Score at Week 4 | The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). | Full Analysis Set consisted of all subjects in the safety population who had baseline and at least on post-baseline efficacy data and met the objectively-measured major eligibility criteria. Last observation carried forward method for missing data. | Posted | Mean | Standard Deviation | Scores on a scale | Baseline and Week 4 |
|
|
|
| Secondary | Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) for Each Question's Score at Week 8 | The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). | Full Analysis Set consisted of all subjects in the safety population who had baseline and at least on post-baseline efficacy data and met the objectively-measured major eligibility criteria. Last observation carried forward method for missing data. | Posted | Mean | Standard Deviation | Scores on a scale | Baseline and Week 8 |
|
|
|
| Secondary | Percentage of Change From Baseline in Hamilton Rating Scale for Depression (HAM-D)for Each Question's Score at Week 4 | The Hamilton Rating Scale for Depression (HAM-D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM-D score range from 0 (not ill) to 53 (severely ill). | Full Analysis Set consisted of all subjects in the safety population who had baseline and at least on post-baseline efficacy data and met the objectively-measured major eligibility criteria. Last observation carried forward method for missing data. | Posted | Mean | Standard Deviation | Percentage of Change | Baseline and Week 4 |
|
|
|
| Secondary | Percentage of Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) for Each Question's Score at Week 8 | The Hamilton Rating Scale for Depression (HAM-D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). | Full Analysis Set consisted of all subjects in the safety population who had baseline and at least on post-baseline efficacy data and met the objectively-measured major eligibility criteria. Last observation carried forward method for missing data. | Posted | Mean | Standard Deviation | Percentage of Change | Baseline and Week 8 |
|
|
|
| Secondary | Hamilton Rating Scale for Depression (HAM-D) Total Score at Week 4 and Week 8 | The Hamilton Rating Scale for Depression (HAM-D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). | Full Analysis Set consisted of all subjects in the safety population who had baseline and at least on post-baseline efficacy data and met the objectively-measured major eligibility criteria. Last observation carried forward method for missing data. | Posted | Mean | Standard Deviation | Scores on a scale | Week 4 and Week 8 |
|
|
|
| Secondary | Percentage of Responders Based on the Clinical Global Impression - Global Improvement Score (CGI-I)at Week 4 and Week 8 | The CGI-I assesses the investigator's impression of the patient's current illness. The time span is the week before the rating and the score ranges from 1 (very much improved) to 7 (very much worse). Responders are subjects that have a score of 1 (very much improved) or 2 (much improved) on the CGI-I. | Full Analysis Set consisted of all subjects in the safety population who had baseline and at least on post-baseline efficacy data and met the objectively-measured major eligibility criteria. Last observation carried forward method for missing data. | Posted | Number | Percentage of Responders | Week 4 and Week 8 |
|
|
|
| Secondary | Change From Baseline in Clinical Global Impression (CGI) Severity of Illness Score at Weeks 1, 2, 3, 4, 8 | The CGI-S assesses the investigator's impression of the severity of the patient's current illness. The time span is the week before the rating and the score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). | Full Analysis Set consisted of all subjects in the safety population who had baseline and at least on post-baseline efficacy data and met the objectively-measured major eligibility criteria. Last observation carried forward method for missing data. | Posted | Mean | Standard Deviation | Scores on a scale | Baseline, Weeks 1, 2, 3, 4, 8 |
|
|
|
| Secondary | Adverse Events (>=5% Incidence) | Safety population - all subjects who took at least one dose of study medication. | Posted | Number | Participants | Baseline through Week 8 |
|
|
|
| Secondary | Serious Adverse Events | Safety population - all subjects who took at least one dose of study medication. | Posted | Number | Participants | Baseline through Week 8 |
|
|
|
| 1 |
| 31 |
| Constipation | Gastrointestinal disorders | MedDRA | Systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA | Systematic Assessment |
|
| Nasopharyngitis | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
|
| Pyrexia | General disorders | MedDRA | Systematic Assessment |
|
| Thirst | General disorders | MedDRA | Systematic Assessment |
|
| Weight decrease | Metabolism and nutrition disorders | MedDRA | Systematic Assessment |
|
| Glossitis | Gastrointestinal disorders | MedDRA | Systematic Assessment |
|
| Paraesthesia oral | Nervous system disorders | MedDRA | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA | Systematic Assessment |
|
| Irritability | Psychiatric disorders | MedDRA | Systematic Assessment |
|
| Edema Peripheral | Blood and lymphatic system disorders | MedDRA | Systematic Assessment |
|
| Somnolence | Psychiatric disorders | MedDRA | Systematic Assessment |
|
| Blood Pressure increased | Cardiac disorders | MedDRA | Systematic Assessment |
|
| Pruritus | General disorders | MedDRA | Systematic Assessment |
|
| Depression | Psychiatric disorders | MedDRA | Systematic Assessment |
|
| Excoriation | Skin and subcutaneous tissue disorders | MedDRA | Systematic Assessment |
|
| Back Pain | General disorders | MedDRA | Systematic Assessment |
|
GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
| D001519 |
| Behavior |
| Title | Measurements |
|---|---|
|
| Insomnia Early |
|
| Insomnia Middle |
|
| Insomnia Late |
|
| Work/Activities |
|
| Retardation |
|
| Anxiety Psychic |
|
| Anxiety Somatic |
|
| Somatic Symptoms GI |
|
| Somatic Symptoms General |
|
| Genital Symptoms |
|
| Hypochondriasis |
|
| Lose Weight History |
|
| Insight |
|
| Title | Measurements |
|---|---|
|
| Insomnia Early |
|
| Insomnia Middle |
|
| Insomnia Late |
|
| Work/Activities |
|
| Retardation |
|
| Agitation |
|
| Anxiety Psychic |
|
| Anxiety Somatic |
|
| Somatic Symptoms GI |
|
| Somatic Symptoms General |
|
| Genital Symptoms |
|
| Hypochondriasis |
|
| Lose Weight History |
|
| Insight |
|
| Title | Measurements |
|---|---|
|
| Insomnia Early |
|
| Insomnia Middle |
|
| Insomnia Late |
|
| Work/Activities |
|
| Retardation |
|
| Agitation |
|
| Anxiety Psychic |
|
| Anxiety Somatic |
|
| Somatic Symptoms GI |
|
| Somatic Symptoms General |
|
| Genital Symptoms |
|
| Hypochondriasis |
|
| Lose Weight History |
|
| Insight |
|
| Title | Measurements |
|---|---|
|
| Insomnia Early |
|
| Insomnia Middle |
|
| Insomnia Late |
|
| Work/Activities |
|
| Retardation |
|
| Agitation |
|
| Anxiety Psychic |
|
| Anxiety Somatic |
|
| Somatic Symptoms GI |
|
| Somatic Symptoms General |
|
| Genital Symptoms |
|
| Hypochondriasis |
|
| Lose Weight History |
|
| Insight |
|
| Title | Measurements |
|---|---|
|
| Week 4 |
|
| Week 8 |
|